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Genetic determinants of the homocysteine level. Elevated total THE 5,10-METHYLENETETRAHYDROFOLATE
homocysteine (tHcy) plasma concentrations indicate folate REDUCTASE GENE (MTHFR)
and/or vitamin B12 deficiency and are associated with cardiovas-
The human 5,10-methylenetetrahydrofolate reductasecular disease and neural tube defects. Evidence has accumu-
gene (MTHFR, OMIM 607093) is located on chromo-lated that folate-, vitamin B12-, and Hcy-metabolism are under
genetic control. Because Hcy metabolism is impaired in renal some 1p36.3. The MTHFR gene product consists of 656
failure, MTHFR 677 CT, GCP2 1561CT, RFC1 80GA, and amino acid residues (MTHFR, EC 1.5.1.20) and repre-
TCN2 776GC may further aggravate hyperhomocysteinemia sents a key enzyme in the folate cycle. It reduces 5,10-
in these patients. The most consistent effect on tHcy plasma
methylenetetrahydrofolate to 5-methyltetrahydrofolate,concentrations is observed for 677CT of MTHFR, whereas
thus catalyzing the only reaction in the cell that ulti-GCP2, RFC1, and TCN2 polymorphisms show no major effect
mately generates 5-methyltetrahydrofolate, the biologi-on tHcy concentrations. Much is yet to be learned about the
impact of genetic variants on tHcy levels, human diseases, the cally active folate derivative.
genetic-nutrient interactions, as well as the pharmacogenetic Three polymorphisms exist in MTHFR that are located
consequences in Hcy and vitamin metabolism. at nucleotide position 677 (MTHFR 677CT), position
1298 (MTHFR 1298AC), and position 1317 (MTHFR
1317TC). MTHFR 677CT occurs in exon 4 at the
Elevated total homocysteine (tHcy) plasma concentra- folate-binding site and changes an alanine into a valine
tions indicate folate and/or vitamin B12 deficiency and residue (A222V). MTHFR 1298AC is located in exon
are associated with cardiovascular disease and neural 7 within the presumptive regulatory domain, changing
tube defects. Evidence has accumulated that folate-, vita- a glutamic acid into an alanine residue (E429A). The
min B12-, and Hcy-metabolism are under genetic control MTHFR 1317TC is a silent mutation that is also located
(Fig. 1). Because Hcy metabolism is impaired in renal in exon 7. MTHFR 677CT, MTHFR 1298AC, as well
failure, these mutations could further contribute to hyp- as compound heterozygosity for 1298AC and 677CT,
erhomocysteinemia of end-stage renal disease patients. is associated with a reduced enzyme activity of 45%,
In particular, the MTHFR 677CT genotype influences 68%, and 42%, respectively.
folate and tHcy concentrations [1]. Recently, two other The MTHFR 677TT genotype is present in about 12%
polymorphisms located in the genes coding for glutamate of the general population and shows a heterogeneous
carboxypeptidase II (GCP2 1561CT; H475Y), and for distribution among ethnic groups, with an allele fre-
reduced folate carrier 1 (RFC1 80GA; R27H) have quency ranging from 0.045 in Sri Lanka to 0.3 in Cauca-
sians and Americans. MTHFR 1298AC shows an allelebeen suggested to be associated with alterations in Hcy
frequency of 0.3 among Canadians, Austrians, and Dutchand folate metabolism [2, 3]. Furthermore, a polymor-
individuals. The allele frequency of MTHFR 1317TCphism in the transcobalamin II gene (TCN2) (776CG;
is 0.05 among Canadian individuals, 0.059 in a TurkishP259R) affects transcobalamin plasma concentration
population, and was quite common in a small populationand, thus, may interfere with cellular vitamin B12 avail-
of Africans. In one study, none of 1000 healthy Cauca-ability and Hcy metabolism [4]. The aim of this mini-
sians and only one of 1000 coronary artery disease pa-review is to provide an overview of polymorphisms of
tients tested positive for MTHFR 1317TC.MTHFR, GCP2, RFC1, and TCN2 that may affect folate,
MTHFR 677CT mutation is associated with de-vitamin B12, and Hcy metabolism.
creased formation of 5-methyltetrahydrofolate and an
accumulation of formylated tetrahydrofolate polygluta-
mates in erythrocytes. Furthermore, MTHFR 677TT is fre-Key words: homosysteine, B12 deficiency, transcobalamin II, reduced
folate carrier 1, glutamate carboxypeptidase. quently associated with higher tHcy plasma levels as com-
pared to heterozygotes or people without mutation. This 2003 by the International Society of Nephrology
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Table 1. Effects of RFC1 80GA on plasma folate, red blood cell
folate, plasma tHcy, cardiovascular disease, and neural tube defects
P folate RBC folate tHcy CVD NTD
Chango [3] — — — ND ND
De Marco [14] ND ND ND ND ↓
Shaw [15] ND ND ND ND —
Submitteda — — — ND ND
Abbreviations are: P folate, plasma folate; RBC folate, red blood cell folate;
tHcy, total homocysteine; CVD, cardiovascular disease; NTD, neural tube de-
fects, ND, not done, no effect.
a Dialysis patients
velopment of embryos, providing folate transport across
the placenta. Furthermore, a 58 kD protein has been de-
tected in the brush border membrane of the murine intes-
Fig. 1. Determinants of Hcy metabolism. Gene symbols (shown in ital- tine, which mediates intestinal folate transport.ics) are: MTHFR, 5, 10-methylenetetrahydrofolate reductase gene; RFC1,
In RFC1, a polymorphism (RFC1 80GA) exists thatreduced folate carrier 1 gene; GCP2, glutamate carboxypeptidase II
gene; BHMT, betaine homocysteine methyltransferase gene; CBS, cys- is located at nucleotide position 80 in exon 2 and changes
tathionine -synthase gene; TCN2, transcobalamin II gene; MTRR, an arginine into a histidine residue (R27H) [3]. Amongmethionine synthase reductase gene; MTR, methionine synthase gene.
healthy French adults, homozygosity for the mutant A
allele has been observed in 21.9% of individuals [3].
The RFC1 80GA mutation did not affect plasma
effect is observed in all countries and regions of Europe. folate or red blood cell folate concentrations of French
In renal failure patients, this polymorphism shows a ma- unselected healthy individuals, and showed only a trend
jor effect on tHcy plasma concentrations [5–8]. toward higher tHcy levels in subjects with the RFC1
MTHFR 1298AC alone influences neither folate sta- 80GG genotype [3] (Table 1). In some individuals show-
tus nor tHcy concentrations. By contrast, compound het- ing the combined RFC1 80GG/MTHFR 677TT geno-
erozygosity for the 677T and the 1298C allele can be type, significantly higher tHcy levels and lower red blood
associated with decreased folate plasma concentrations cell folate levels have been observed as compared to
and higher tHcy concentrations. individuals with RFC1 80GG/MTHFR 677CC or RFC1
The implications of MTHFR 677CT and MTHFR 80GG/MTHFR 677CT [3].
1298AC in various diseases, including renal failure, are In another study, a decreased frequency of the RFC1
discussed in other articles [9, 10]. The MTHFR 1317TC 80A allele among neural tube defect–affected children
mutation is not associated with vascular disease. and their parents was observed [14]. In contrast, no in-
The MTHFR 677TT and the MTHFR 677CT/1298AC creased risk for neural tube defects was observed by
genotypes can modulate the efficacy of oral or intrave- others [15]. Association studies of RFC1 with cardiovas-
nous folic- or folinic- acid therapy [11, 12]. Furthermore, cular disease are not available at present. In renal failure
the effect of drugs that interfere with the folate status is patients, no effect of RFC1 on plasma or red cell folate
possibly influenced by MTHFR 677CT. Most recently, or tHcy concentrations were observed by Fo¨dinger et al
vitamin B2 availability was shown to influence tHcy (J Am Soc Nephrol, in press) among 120 hemodialysis
plasma concentrations in renal failure patients [13]. This patients (Table 1).
finding may point to a gene-nutrient interaction because
vitamin B2 status is of particular importance for tHcy THE GLUTAMATE CARBOXYPEPTIDASE IIlevels of MTHFR 677TT individuals.
GENE (GCP2)
The human glutamate carboxypeptidase II gene (GCP2,
THE REDUCED FOLATE CARRIER 1 OMIM 600934, contains alternative titles and symbols)
GENE (RFC1) is located on chromosome 11p11.2.
The GCP2 gene product consists of 750 amino acid res-The human reduced folate carrier 1 gene (RFC1,
OMIM 600424, includes alternative titles and symbols) idues and is termed folylpoly--glutamate carboxypeti-
dase (FGCP). Folylpoly--glutamate carboxypetidase isis located on chromosome 21q22.3. The RFC1 gene prod-
uct consists of 591 amino acid residues and is termed an exopeptidase that is anchored to the apical brush bor-
der membrane and shows folate hydrolase and N-ace-human folate transporter (FOLT), which belongs to the
SLC19A family of transporters. tylated -linked acidic dipeptidase activity. It hydrolyzes
the terminal glutamate residues of dietary folylpoly--The folate transporter is possibly important for the de-
Sunder-Plassmann and Fo¨dinger: Genetics of homocysteine metabolism S-143
Table 3. Effect of TCN2 on plasma tHcy, methyl malonic acid,Table 2. Effect of GCP2 on plasma folate, red blood cell folate,
plasma tHcy, cardiovascular disease, and neural tube defects vitamin B12, holotranscobalamin II, and transcobalamin II levels
tHcy MMA B12 HTC II TC II CVD NTDP folate RBC folate tHcy CVD NTD
Devlin [2] ↓ — ↑ ND ND Namour [4] ↑ ND — ND ↓ ND ND
McCaddon [19] — ND — ND ND ND NDBrancaccio [16] ND ND ND ND ↓
Vargas- Miller [20] — ↑ ↓ ↓ ND ND ND
Afman [21] ↑(NS) ND — ↓ ↓ ND —Martinez [17] — ND — ND ND
Lievers [18] ↑ ↑ — — ND Lievers [22] (↑) ND — ND ND — ND
Submitteda — ND — — ND ND NDSubmitteda — ↑ — ND ND
Abbreviations are: tHcy, total homocysteine; MMA, methylmalonic acid; B12,Abbreviations are: P folate, plasma folate; RBC folate, red blood cell folate;
tHcy, total homocysteine; CVD, cardiovascular disease; NTD, neural tube de- vitamin B12; HTC II, holotranscobalamin II; TC II, transcobalamin II; CVD,
cardiovascular disease; NTD, neural tube defects; ND, not done; NS, not signifi-fects; ND, not done, no effect.
a Dialysis patients cant, no effect.
a Dialysis patients
glutamates before absorption. Thereafter, the monoglu-
B12) is rapidly cleared from plasma. The cellular uptaketamyl folate derivatives are transported through the mem-
is mediated by receptor-mediated endocytosis.brane via the folate transporter. Therefore, FGCP possi-
There are at least two reactions in humans that arebly regulates the availability of dietary folates.
catalyzed by cobalamin (Cbl, vitamin B12) dependentIn GCP2, a polymorphism (GCP2 1561CT) exists
enzymes (L-methylmalonic-CoA mutase and methioninethat is located in exon 13 at the putative catalytic domain
synthase). The former requires adenosyl-Cbl and cata-of the enzyme and is associated with a 53% reduction
lyzes the conversion of L-methylmalonyl-CoA to succi-of enzyme acitivity [2]. Among 75 healthy Caucasians,
nyl-CoA. The latter requires CH3-Cbl and catalyzes thethe allele frequency was 0.04. The genotype frequency
conversion of 5-CH3-tetrahydrofolate and Hcy to tetra-was 8% for heterozygotes and 92% for the homozygote
hydrofolate and methionine, thus playing a central role inwild-type genotype [2].
one carbon metabolism. In case of vitamin B12 deficiency,The GCP2 1561CT mutation is associated with lower
Hcy and/or methylmalonic acid can accumulate in theserum folate levels and higher serum tHcy concentra-
plasma. Holo-TC II concentrations possibly are sensitivetions, whereas no relation has been found with red blood
and early indicators of vitamin B12 deficiency becausecell folate or vitamin B12 levels [2] (Table 2). Further-
they reflect biologically available vitamin B12.more, no relationship was observed between the pres-
Several polymorphisms of TCN2 have been described.ence of MTHFR 677CT and GCP2 1561CT with re-
One of these variants (776GC P259R) affects TC IIspect to folate status and Hcy concentrations [2].
plasma concentration and may interfere with vitaminAmong Italian neural tube defect patients, a decreased
B12 cellular availability and Hcy metabolism in healthyfrequency of the GCP2 1561T allele has been reported [16].
individuals. The frequency of C homozygotes was 34.6%,GCP2 1561CT showed no association with plasma fo-
47.8% for heterozygotes, and 17.6% for G homocygoteslate or plasma tHcy concentrations in 1324 participants
among healthy Caucasians [4]. More precisely, bloodof the fifth examination of the Framingham Offspring
apo-TC II concentrations of GG homozygotes were higherStudy [17]. A study of 190 vascular disease patients and
as compared to heterozygotes or individuals without mu-601 healthy controls showed that GCP2 1561CT is as-
tation (Table 3). Heterozygotes showed higher tHcy con-sociated with elevated red blood cell folate and plasma
centrations as compared to both homozygous genotypesfolate levels and has no effect on vitamin B12 levels [18].
[4]. In contrast, no effect of TCN2 776CG on plasmaIn this study, no association of GCP2 1561CT with car-
folate, plasma B12, or plasma tHcy concentrations was re-diovascular disease or with plasma tHcy levels was ob-
ported in healthy subjects and dementia patients [19].served. In our study of hemodialysis patients, we also ob-
TCN2 776CG was associated with elevated plasmaserved a red blood cell folate elevating effect of the
methylmalonic acid levels and a decrease of holo-TC II,T allele, whereas plasma folate and plasma tHcy were not
and had no effect on plasma tHcy or vitamin B12 [20].affected (J Am Soc Nephrol, in press) (Table 2).
More recently, the association of five polymorphisms in
TCN2 with holo-TC II, total-TC II, and red blood cell
THE TRANSCOBALAMIN II GENE (TCN2) vitamin B12 was investigated [21]. None of these polymor-
phisms showed an effect on tHcy levels, nor were theyThe transcobalamin II gene (TCN2, OMIM 275350)
has been mapped to chromosome 22q11.2-qter. The associated with an increased neural tube defect risk.
However, the 776CG variant resulted in decreased to-TCN2 gene product is termed transcobalamin II (TC II)
and consists of 409 amino acid residues. It is a plasma tal-TC II concentrations, decreased holo-TC II concen-
trations, and a trend for elevated tHcy concentrations.globulin and represents one of three vitamin B12 binding
proteins in humans. Holo-TC II (apo-TC II  vitamin There was no effect on vitamin B12 levels. In another
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to T) in the methylenetetrahydrofolate reductase gene aggravatesstudy [22], no different genotype distribution of TCN2
hyperhomocysteinemia in hemodialysis patients. Kidney Int 52:
776CG was observed between cardiovascular disease 517–523, 1997
6. Vychytil A, Fo¨dinger M, Wo¨lfl G, et al: Major determinants ofpatients and healthy individuals. In subjects with the
hyperhomocysteinemia in peritoneal dialysis patients. Kidney Inthighest quartile of the vitamin B12 distribution (299 53:1775–1782, 1998
pmol/L), tHcy concentrations were lower in subjects with 7. Fo¨dinger M, Wo¨lfl G, Fischer G, et al: Effect of MTHFR 677CT
on plasma total homocysteine levels in renal graft recipients. Kid-TCN2 776CG. Therefore, GG individuals would par-
ney Int 55:1072–1080, 1999ticularly benefit from high vitamin B12 concentrations 8. Fo¨dinger M, Buchmayer H, Heinz G, et al: Effect of MTHFR
with respect to tHcy concentration, suggesting a gene- 1298AC and MTHFR 677CT genotypes on total homocysteine,
folate, and vitamin B12 plasma concentrations in kidney graft recipi-environment interaction [22]. We observed no effect of
ents. J Am Soc Nephrol 11:1918–1925, 2000TCN2 776CG on tHcy, B12, or holotranscobalamin II
9. Fo¨dinger M, Ho¨rl WH, Sunder-Plassmann G: Molecular biol-
plasma concentrations among 120 dialysis patients (manu- ogy of 5,10-methylenetetrahydrofolate reductase. J Nephrol 13:20–
33, 2000script submitted for publication), Table 3.
10. Ueland PM, Hustad S, Schneede J, et al: Biological and clinical
implications of the MTHFR C677T polymorphism. Trends Phar-
macol Sci 22:195–201, 2001CONCLUSIONS
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Soc Nephrol 11:1106–1116, 2000The most consistent effect on tHcy plasma concentra-
13. Skoupy S, Fo¨dinger M, Veitl M, et al: Riboflavin is a determinant
tions is observed for 677CT of MTHFR, whereas GCP2, of total homocysteine plasma concentrations in end-stage renal
disease patients. J Am Soc Nephrol 13:1331–1337, 2002RFC1, and TCN2 polymorphisms show no major effect
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